Enhanced in vitro osteoblast differentiation on TiO2 scaffold coated with alginate hydrogel containing simvastatin

Journal of Tissue Engineering

Volumn 4, Issue 1, 2013, Pages 1-12

  Pullisaar, Helen ^a   Tiainen, Hanna ^a   Landin, Maria A ^a   Lyngstadaas, Ståle P ^a   Haugen, Håvard J ^a   Reseland, Janne E ^a   Østrup, Esben ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alginate hydrogel; Bone morphogenetic protein 2; Osteocalcin; Scaffold; Simvastatin; Vascular endothelial growth factor A

Indexed keywords

ALGINATE; BONE; CELL ENGINEERING; COMPUTERIZED TOMOGRAPHY; CYTOTOXICITY; ENDOTHELIAL CELLS; HYDROGELS; OSTEOBLASTS; PHOSPHATASES; POLYMERASE CHAIN REACTION; SCAFFOLDS (BIOLOGY); SCANNING ELECTRON MICROSCOPY;

ALGINATE HYDROGELS; BONE GRAFT MATERIALS; BONE MORPHOGENETIC PROTEIN-2; IN-VITRO; OSTEOBLAST DIFFERENTIATION; OSTEOCALCIN; OSTEOPROTEGERIN; SIMVASTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

TITANIUM DIOXIDE;

ALGINIC ACID; ALKALINE PHOSPHATASE; CALCIUM; MOLECULAR SCAFFOLD; OSTEOCALCIN; OSTEOPROTEGERIN; SIMVASTATIN; TITANIUM DIOXIDE; VASCULOTROPIN A;

ADOLESCENT; ADULT; ARTICLE; BONE DEVELOPMENT; BONE REGENERATION; CELL CULTURE; CELL DIFFERENTIATION; CHILD; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROGEL; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; MALE; MICRO-COMPUTED TOMOGRAPHY; OSTEOBLAST; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SCANNING ELECTRON MICROSCOPY; SCHOOL CHILD; SYNTHETIC BONE GRAFT;

EID: 84890243173     PISSN: None     EISSN: 20417314     Source Type: Journal    
DOI: 10.1177/2041731413515670     Document Type: Article

References (57)

1. Giannoudis PV, Chris Arts JJ, Schmidmaier G, et al. What should be the characteristics of the ideal bone graft substitute? Injury 2011; 42(Suppl. 2): S1-S2.
2. Dimitriou R, Mataliotakis GI, Angoules AG, et al. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury 2011; 42(Suppl. 2): S3-S15.
3. Ben-David D, Srouji S, Shapira-Schweitzer K, et al. Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. Biomaterials 2013; 34(12): 2902-2910.
4. Zieris A, Chwalek K, Prokoph S, et al. Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. J Control Release 2011; 156(1): 28-36.
5. Zheng F, Wang S, Wen S, et al. Characterization and antibacterial activity of amoxicillin-loaded electrospun nano-hydroxyapatite/poly(lactic-co-glycolic acid) composite nanofibers. Biomaterials 2013; 34(4): 1402-1412.
6. Monjo M, Rubert M, Ellingsen J, et al. Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Cell Physiol Biochem 2010; 26(4-5): 647-656.
7. Vo TN, Kasper FK and Mikos AG. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliver Rev 2012; 64(12): 1292-1309.
8. Park YS, David AE, Park KM, et al. Controlled release of simvastatin from in situ forming hydrogel triggers bone formation in MC3T3-E1 cells. AAPS J 2013; 15(2): 367-376.
9. Bae MS, Yang DH, Lee JB, et al. Photo-cured hyaluronic acid-based hydrogels containing simvastatin as a bone tissue regeneration scaffold. Biomaterials 2011; 32(32): 8161-8171.
10. Wadagaki R, Mizuno D, Yamawaki-Ogata A, et al. Osteogenic induction of bone marrow-derived stromal cells on simvastatin-releasing, biodegradable, nano- to microscale fiber scaffolds. Ann Biomed Eng 2011; 39(7): 1872-1881.
11. Ito T, Saito M, Uchino T, et al. Preparation of injectable auto-forming alginate gel containing simvastatin with amorphous calcium phosphate as a controlled release medium and their therapeutic effect in osteoporosis model rat. J Mater Sci: Mater M 2012; 23(5): 1291-1297.
12. Liao JK and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol 2005; 45: 89-118.
13. Pagkalos J, Cha JM, Kang Y, et al. Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res 2010; 25(11): 2470-2478.
14. Ahn KS, Sethi G, Chaturvedi MM, et al. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 2008; 123(8): 1733-1740.
15. Fukui T, Ii M, Shoji T, et al. Therapeutic effect of local administration of low-dose simvastatin-conjugated gelatin hydrogel for fracture healing. J Bone Miner Res 2012; 27(5): 1118-1131.
16. Monjo M, Rubert M, Wohlfahrt JC, et al. In vivo performance of absorbable collagen sponges with rosuvastatin in critical-size cortical bone defects. Acta Biomater 2010; 6(4): 1405-1412.
17. Walter MS, Frank MJ, Rubert M, et al. Simvastatin-activated implant surface promotes osteoblast differentiation in vitro. J Biomater Appl. Epub ahead of print 2 May 2013. DOI: 10.1177/0885328213486364.
18. Nyan M, Hao J, Miyahara T, et al. Accelerated and enhanced bone formation on novel simvastatin-loaded porous titanium oxide surfaces. Clin Implant Dent R. Epub ahead of print 7 February 2013. DOI: 10.1111/cid.12045.
19. Chu TM, Warden SJ, Turner CH, et al. Segmental bone regeneration using a load-bearing biodegradable carrier of bone morphogenetic protein-2. Biomaterials 2007; 28(3): 459-467.
20. Kolambkar YM, Dupont KM, Boerckel JD, et al. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 2011; 32(1): 65-74.
21. Nath SD, Linh NT, Sadiasa A, et al. Encapsulation of simvastatin in PLGA microspheres loaded into hydrogel loaded BCP porous spongy scaffold as a controlled drug delivery system for bonetissue regeneration. J Biomater Appl. Epub ahead of print 12 September 2013. DOI: 10.1177/0885328213499272.
22. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials 2000; 21(24): 2529-2543.
23. Bose S, Roy M and Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trends Biotechnol 2012; 30(10): 546-554.
24. Tiainen H, Wiedmer D and Haugen HJ. Processing of highly porous TiO2 bone scaffolds with improved compressive strength. J Eur Ceram Soc 2013; 33(1): 15-24.
25. Verket A, Tiainen H, Haugen H, et al. Enhanced osteoblast differentiation on scaffolds coated with TiO2 compared to SiO2 and CaP coatings. Biointerphases 2012; 7(1-4): 1-10.
26. Sabetrasekh R, Tiainen H, Reseland J, et al. Impact of trace elements on biocompatibility of titanium scaffolds. Biomed Mater 2010; 5(1): 015003.
27. Gomez-Florit M, Rubert M, Ramis JM, et al. TiO2 scaffolds sustain differentiation of MC3T3-E1 cells. J Biomater Tiss Eng 2012; 2(4): 336-344.
28. Tiainen H, Wohlfahrt JC, Verket A, et al. Bone formation in TiO2 bone scaffolds in extraction sockets of minipigs. Acta Biomater 2012; 8(6): 2384-2391.
29. Haugen HJ, Monjo M, Rubert M, et al. Porous ceramic titanium dioxide scaffolds promote bone formation in rabbit peri-implant cortical defect model. Acta Biomater 2013; 9(2): 5390-5399.
30. Tiainen H, Lyngstadaas SP, Ellingsen J, et al. Ultra-porous titanium oxide scaffold with high compressive strength. J Mater Sci: Mater M 2010; 21(10): 2783-2792.
31. Takahashi Y and Tabata Y. Homogeneous seeding of mesenchymal stem cells into nonwoven fabric for tissue engineering. Tissue Eng 2003; 9(5): 931-938.
32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29(9): e45.
33. Ruiz-Gaspa S, Nogues X, Enjuanes A, et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 2007; 101(6): 1430-1438.
34. Maeda T, Matsunuma A, Kurahashi I, et al. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 2004; 92(3): 458-471.
35. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286(5446): 1946-1949.
36. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355(9222): 2185-2188.
37. Solomon DH, Finkelstein JS, Wang PS, et al. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidem Dr S 2005; 14(4): 219-226.
38. Rejnmark L, Buus HN, Vestergaard P, et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004; 19(5): 737-744.
39. Wada Y, Nakamura Y and Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 2000; 160(18): 2865.
40. Van Staa T-P, Wegman S, De Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285(14): 1850-1855.
41. Bellosta S, Bernini F, Paoletti R, et al. Non-lipid-related effects of statins. Ann Med 2000; 32(3): 164-176.
42. Langer R. Drug delivery and targeting. Nature 1998; 392: (Suppl. 6679): 5-10.
43. Zhang SM, Cui FZ, Liao SS, et al. Synthesis and biocompatibility of porous nano-hydroxyapatite/collagen/alginate composite. J Mater Sci: Mater M 2003; 14(7): 641-645.
44. Luginbuehl V, Wenk E, Koch A, et al. Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration. Pharm Res 2005; 22(6): 940-950.
45. Lin HR and Yeh YJ. Porous alginate/hydroxyapatite composite scaffolds for bone tissue engineering: preparation, characterization, and in vitro studies. J Biomed Mater Res B 2004; 71(1): 52-65.
46. Shapiro L and Cohen S. Novel alginate sponges for cell culture and transplantation. Biomaterials 1997; 18(8): 583-590.
47. Stein GS, Lian JB, Stein JL, et al. Transcriptional control of osteoblast growth and differentiation. Physiol Rev 1996; 76(2): 593-629.
48. Prockop DJ and Kivirikko KI. Heritable diseases of collagen. N Engl J Med 1984; 311(6): 376-386.
49. Thirunavukkarasu M, Selvaraju V, Dunna NR, et al. Simvastatin treatment inhibits hypoxia inducible factor 1-alpha-(HIF-1alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis after myocardial infarction in streptozotocin-induced diabetic rat. Int J Cardiol 2013; 168(3): 2474-2480.
50. Ahmad T, Kumar M, Mabalirajan U, et al. Hypoxia response in asthma. Am J Resp Cell Mol 2012; 47(1): 1-10.
51. Mayr-Wohlfart U, Waltenberger J, Hausser H, et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002; 30(3): 472-477.
52. Schmid J, Wallkamm B, Hämmerle CH, et al. The significance of angiogenesis in guided bone regeneration. A case report of a rabbit experiment. Clin Oral Implan Res 2002; 8(3): 244-248.
53. Faure C, Linossier M-T, Malaval L, et al. Mechanical signals modulated vascular endothelial growth factor-A (VEGF-A) alternative splicing in osteoblastic cells through actin polymerisation. Bone 2008; 42(6): 1092-1101.
54. Dumas V, Perrier A, Malaval L, et al. The effect of dual frequency cyclic compression on matrix deposition by osteoblast-like cells grown in 3D scaffolds and on modulation of VEGF variant expression. Biomaterials 2009; 30(19): 3279-3288.
55. Faure C, Vico L, Tracqui P, et al. Functionalization of matrices by cyclically stretched osteoblasts through matrix targeting of VEGF. Biomaterials 2010; 31(25): 6477-6484.
56. Vermeulen A, Vermeer C and Bosman FT. Histochemical detection of osteocalcin in normal and pathological human bone. J Histochem Cytochem 1989; 37(10): 1503-1508.
57. Lian JB and Stein GS. Concepts of osteoblast growth and differentiation: basis for modulation of bone cell development and tissue formation. Crit Rev Oral Biol M 1992; 3(3): 269-305.